Central nervous system (CNS) metastases are a common complication in patients with
epidermal growth factor receptor (EGFR)‐mutated non‐small cell lung cancer (NSCLC) …

Purpose Non-small cell lung cancer (NSCLC) patients with EGFR mutation are suffering
from a high incidence of brain metastasis (BM). It is still controversial whether cranial …

Objective Epidermal growth factor receptor (EGFR) mutation is a positive prognostic factor
for survival in patients with non–small-cell lung cancer (NSCLC). In such patients, brain …

Purpose Central nervous system (CNS) is the prevalent site for metastases in epidermal
growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI)-relapsed NSCLC patients. To …

An ideal target-based agent for the treatment of cancer patients should fulfil a number of
requirements, including the availability of biomarkers to select the target population …

Epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) has intracranial
activity in EGFR-mutant Non-Small Cell Lung Cancer (NSCLC). The optimal timing of brain …

Background The first generation epidermal growth factor receptor-tyrosine kinase inhibitors
(EGFR-TKIs), gefitinib and erlotinib, have become the standard first-line treatment for non …

Tyrosine kinase inhibitors (TKIs) of epidermal growth factor receptor (EGFR) were previously
the standard first-line treatments for lung cancers with activating EGFR mutations. The first …

Preferable treatments for epidermal growth factor receptor (EGFR)-mutant non-small cell
lung cancer (NSCLC) with brain metastasis are elusive. The study intended to estimate the …

Brain metastases are a frequent and grave complication of non-small cell lung carcinoma
(NSCLC). The prognosis is generally poor, despite standard therapy based on surgery and …